Quest for the right Drug

|
עמוד הבית / ולטסה 8.4 גר' / מידע מעלון לרופא

ולטסה 8.4 גר' VELTASSA 8.4 G (PATIROMER AS SORBITEX CALCIUM)

תרופה במרשם תרופה בסל נרקוטיקה ציטוטוקסיקה

צורת מתן:

פומי : PER OS

צורת מינון:

אבקה להכנת תרחיף : POWDER FOR ORAL SUSPENSION

Pharmacological properties : תכונות פרמקולוגיות

Pharmacodynamic Properties

5.1     Pharmacodynamic properties
Pharmacotherapeutic group: Drugs for treatment of hyperkalaemia and hyperphosphataemia. ATC code: V03AE09

Mechanism of action

Patiromer is a non-absorbed, cation exchange polymer that contains a calcium-sorbitol complex as a counterion.

Patiromer increases faecal potassium excretion through binding of potassium in the lumen of the gastrointestinal tract. Binding of potassium reduces the concentration of free potassium in the gastrointestinal lumen, resulting in a reduction of serum potassium levels.

Pharmacodynamic effects

In healthy adult subjects, patiromer caused a dose-dependent increase in faecal potassium excretion, and a corresponding decrease in urinary potassium excretion with no change in serum potassium.
25.2 g of patiromer, administered once daily for 6 days, resulted in a mean increase in faecal potassium excretion of 1283 mg/day, and a mean decrease in urinary potassium excretion of 1438 mg/day. Daily urinary calcium excretion increased from baseline by 53 mg/day.

In an open-label study to assess the time to onset of action, a statistically significant reduction in serum potassium in hyperkalaemic patients was observed at 7 hours after the first dose. Following discontinuation of patiromer, potassium levels remained stable for 24 hours after the last dose, then rose again during a 4-day observation period.

Clinical efficacy and safety

Overall, in the phase 2 and 3 clinical trials, 99.5% of patients were receiving RAAS inhibitor therapy at baseline, 87.0% had CKD with eGFR <60 mL/min/1.73 m2, 65.6% had diabetes mellitus and 47.5% had heart failure.

Study 1 (OPAL-HK)
The safety and efficacy of patiromer were demonstrated in a two-part, single-blind randomised withdrawal study that evaluated this treatment in hyperkalaemic patients with chronic kidney disease (CKD) on stable doses of at least one RAAS inhibitor (i.e. angiotensin-converting enzyme inhibitor [ACEI], angiotensin II receptor blocker [ARB] or mineralocorticoid receptor antagonist [MRA]).



In Part A, 243 patients were treated with patiromer for 4 weeks. Patients with a baseline serum potassium of 5.1 mEq/L to <5.5 mEq/L (mmol/L) received a starting dose of 8.4 g patiromer per day (as a divided dose) and patients with a baseline serum potassium of 5.5 mEq/L to <6.5 mEq/L received a starting dose of 16.8 g patiromer per day (as a divided dose). The dose was titrated, as needed, based on the serum potassium level, assessed starting on Day 3 and then at weekly visits to the end of the 4-week treatment period, with the aim of maintaining serum potassium in the target range (3.8 mEq/L to <5.1 mEq/L). The mean daily doses of patiromer were 13 g and 21 g in patients with serum potassium of 5.1 to <5.5 mEq/L and 5.5 to <6.5 mEq/L, respectively.

The mean age of patients was 64 years (54% aged 65 and over, 17% aged 75 and over), 58% of patients were men, and 98% were Caucasian. Approximately 97% of patients had hypertension, 57% had type 2 diabetes, and 42% had heart failure.

Mean serum potassium levels and change in serum potassium from Part A Baseline to Part A Week 4 is shown in Table 1. For the Part A secondary outcome, 76% (95% CI: 70%, 81%) of patients had a serum potassium in the target range of 3.8 mEq/L to <5.1 mEq/L at Part A Week 4.


Table 1:       Patiromer treatment phase (Part A): Primary endpoint
Baseline Potassium                           Overall Population
5.1 to < 5.5 mEq/L     5.5 to <6.5 mEq/L     (n=237)
(n=90)                 (n=147)
Serum Potassium (mEq/L)
Baseline, mean (SD) 5.31 (0.57)             5.74 (0.40)           5.58 (0.51) 
Week 4 Change from      -0.65 ± 0.05              -1.23 ± 0.04             -1.01 ± 0.03 Baseline, Mean ± SE
(95% CI)                (-0.74, -0.55)            (-1.31, -1.16)           (-1.07, -0.95) p-value                                                                    <0.001 
In Part B, 107 patients with a Part A baseline serum potassium of 5.5 mEq/L to <6.5 mEq/L and whose serum potassium was in the target range (3.8 mEq/L to <5.1 mEq/L) at Part A Week 4 and still receiving RAAS inhibitor treatment were randomised to continue patiromer or to receive placebo for 8 weeks to evaluate the effect of withdrawing patiromer on serum potassium. In patients randomised to patiromer, the mean daily dose was 21 g at the start of Part B and during Part B.

The Part B primary endpoint was the change in serum potassium from Part B baseline to the earliest visit at which the patient’s serum potassium was first outside of the range of 3.8 to <5.5 mEq/L or to Part B Week 4 if the patient’s serum potassium remained in the range. In Part B, serum potassium in patients on placebo increased significantly relative to patients who remained on patiromer (p<0.001).

More placebo patients (91% [95% CI: 83%, 99%]) developed a serum potassium ≥5.1 mEq/L at any time during Part B than patiromer patients (43% [95% CI: 30%, 56%]), p<0.001. More placebo patients (60% [95% CI: 47%, 74%]) developed a serum potassium ≥5.5 mEq/L at any time during Part B than patiromer patients (15% [95% CI: 6%, 24%]), p<0.001.

The potential of patiromer to enable concomitant RAAS inhibitor treatment was also assessed in part B. Fifty-two percent (52%) of subjects receiving placebo discontinued RAAS inhibitor treatment because of recurrent hyperkalaemia compared with 5% of subjects treated with patiromer.

Study 2 (AMETHYST-DN)
The effect of treatment with patiromer for up to 52 weeks was evaluated in an open-label study of 304 hyperkalaemic patients with CKD and type 2 diabetes mellitus on stable doses of a RAAS inhibitor.
The mean age of patients was 66 years (59.9% aged 65 and over, 19.7% aged 75 and over), 63% of patients were men, and all were Caucasian. Decreases in serum potassium with patiromer treatment 
were maintained over 1 year of chronic treatment as shown in Figure 1, with a low incidence of hypokalaemia (2.3%) and the majority of subjects reaching (97.7%) and maintaining target serum potassium levels (overall during maintenance period, serum potassium was within the target range for approximately 80% of the time). In patients with a baseline serum potassium of >5.0 to 5.5 mEq/L who received an initial dose of 8.4 g patiromer per day, the mean daily dose was 14 g; in those with a baseline serum potassium of >5.5 to <6.0 mEq/L who received an initial dose of 16.8 g patiromer per day, the mean daily dose was 20 g during the entire study.


Figure 1:                                  Mean (95% CI) serum potassium over Time Baseline Serum K+ > 5.0 to 5.5 mEq/L
Baseline Serum K+ > 5.5 to < 6.0 mEq/L
Mean (95% Cl) Serum Potassium (mEq/L)



Study Visit (week)                                                   Follow- Up
(day)
Number of Subjects:
Lower K+ Stratum: 218 199 192 175 168 161 161 163 158 156 151 148 149 145 131 126 Higher K+ Stratum: 83 73 70 65 62 62 62 61 53 53 53 52 49 49 48 47

Study 3 (PEARL-HF)
The ability of patiromer to enable concomitant spironolactone treatment was investigated in a randomised, double-blind, placebo-controlled study in heart failure patients who were clinically indicated to receive MRA. Patients initiated spironolactone at 25 mg/day at the same time as their randomised treatment (patiromer 12.6 g BID or placebo), and were up-titrated to 50 mg/day after Day 14 if serum potassium was >3.5 and ≤5.1 mEq/L. Of the 105 patients who were randomised and received study treatment (patiromer 56; placebo 49), mean age was 68.3 years, 60.6% were men, 97.1% were Caucasian, and mean eGFR was 81.3 mL/min. Mean baseline serum potassium values were 4.71 mEq/L for patiromer and 4.68 mEq/L for placebo.
The primary efficacy endpoint, change from baseline in serum potassium to the end of the 28-day treatment period, was significantly lower (p<0.001) in the patiromer group (LS mean [SEM]: -0. 21 [0.07] mEq/L) as compared to the placebo group (LS mean [SEM]: +0.23 [0.07] mEq/L). There were also fewer patients in the patiromer group with serum potassium values >5.5 mEq/L (7.3% vs. 24.5%; p=0.027) and more patients on spironolactone 50 mg/day (90.9% versus 73.5%, p=0.022).


Study 4 (AMBER)
The ability of patiromer to enable concomitant spironolactone treatment in patients with resistant hypertension and CKD was further investigated in a randomised, double-blind, placebo-controlled study over 12 weeks. Normokalaemic patients initiated spironolactone at 25 mg per day together with their randomised treatment (patiromer 8.4 g or placebo per day). Patiromer/placebo was titrated weekly (up to 25.2 g per day) to maintain serum potassium ≥4.0 mEq/L and ≤5.1 mEq/L. At week 3 or after, spironolactone dose was increased to 50 mg per day for subjects with systolic blood pressure ≥120 mmHg and serum potassium ≤5.1 mEq/L.
Of the 295 randomized patients receiving study treatment (patiromer 147; placebo 148), mean age was 68.1 years, 51.9% were men, 98.3% were Caucasian, and mean eGFR was 35.73 mL/min/1.73m2. At randomization, mean baseline serum potassium values were 4.74 mEq/L for patiromer and 4.69 mEq/L for placebo. The primary efficacy endpoint, the proportion of subjects remaining on spironolactone at Week 12, was significantly higher (p<0.0001) in the patiromer group (85.7%) compared to the placebo group (66.2%). Significantly more patients received spironolactone 50 mg/day (69.4% versus 51.4%).
Overall, patients in the patiromer group remained on spironolactone 7.1 days longer (95% CI 2.2– 12.0; p=0.0045) compared to the placebo group and received significantly higher cumulative doses of spironolactone (2942.3 (SE 80.1) mg vs 2580.7 (SE 95.8) mg, p=0.0021).
There were also significantly fewer patients in the patiromer group with serum potassium values ≥5.5 mEq/L (35.4% vs. 64.2%, p<0.001).
At Week 12, the mean systolic blood pressure had decreased by 11.0 mmHg (SD 15.34) in the spironolactone + placebo group and by 11.3 mmHg (SD 14.11) in the spironolactone + patiromer group. These decreases from baseline were statistically significant within each treatment group (p<0.0001), but not statistically significant between the groups.

Effect of Food
In an open-label study, 114 patients with hyperkalaemia were randomized to patiromer once daily with food or without food. Serum potassium at the end of treatment, the change from baseline in serum potassium, and the mean dose of patiromer were similar between groups.


Pharmacokinetic Properties

5.2     Pharmacokinetic properties
Patiromer works by binding potassium in the gastrointestinal tract and thus the serum concentration is not relevant for its efficacy. Due to the insolubility and nonabsorptive characteristics of this medicinal product, many classical pharmacokinetic studies cannot be carried out.

Patiromer is excreted approximately 24 to 48 hours after intake, based on average gastrointestinal transit time.

פרטי מסגרת הכללה בסל

א. התרופה תינתן לטיפול בהיפרקלמיה בחולה העונה על כל אלה:1. חולה במחלת כליה כרונית (CKD) דרגות 3 עד 5 שאינו מטופל בדיאליזה;2. לוקה באחד מאלה - מחלה לבבית, יתר לחץ דם עמיד;3. רמת אשלגן בסרום בערך של 5.5 mEq/L ומעלה;4. מטופל בתרופה ממשפחת מעכבי RAAS;5. מיצה טיפול במשתנים מפרישי אשלגן ובדיאטה דלת אשלגן.ב. מתן התרופה ייעשה לפי מרשם של רופא מומחה בנפרולוגיה או מומחה בקרדיולוגיה.

מסגרת הכללה בסל

התוויות הכלולות במסגרת הסל

התוויה תאריך הכללה תחום קליני Class Effect מצב מחלה
א. התרופה תינתן לטיפול בהיפרקלמיה בחולה העונה על כל אלה: 1. חולה במחלת כליה כרונית (CKD) דרגות 3 עד 5 שאינו מטופל בדיאליזה; 2. לוקה באחד מאלה - מחלה לבבית, יתר לחץ דם עמיד; 3. רמת אשלגן בסרום בערך של 5.5 mEq/L ומעלה; 4. מטופל בתרופה ממשפחת מעכבי RAAS; 5. מיצה טיפול במשתנים מפרישי אשלגן ובדיאטה דלת אשלגן. ב. מתן התרופה ייעשה לפי מרשם של רופא מומחה בנפרולוגיה או מומחה בקרדיולוגיה. 01/03/2021 נפרולוגיה היפרקלמיה
שימוש לפי פנקס קופ''ח כללית 1994 לא צוין
תאריך הכללה מקורי בסל 01/03/2021
הגבלות תרופה מוגבלת לרישום ע'י רופא מומחה או הגבלה אחרת

בעל רישום

CTS LTD

רישום

161 52 35491 00

מחיר

0 ₪

מידע נוסף

עלון מידע לרופא

20.04.22 - עלון לרופא 12.12.22 - עלון לרופא 31.07.24 - עלון לרופא 08.10.24 - עלון לרופא

עלון מידע לצרכן

20.04.22 - עלון לצרכן אנגלית 20.04.22 - עלון לצרכן עברית 20.04.22 - עלון לצרכן ערבית 12.12.22 - עלון לצרכן אנגלית 12.12.22 - עלון לצרכן עברית 12.12.22 - עלון לצרכן ערבית 31.07.24 - עלון לצרכן עברית 07.08.24 - עלון לצרכן אנגלית 13.08.24 - עלון לצרכן ערבית 08.10.24 - עלון לצרכן אנגלית 08.10.24 - עלון לצרכן עברית 08.10.24 - עלון לצרכן ערבית 21.01.21 - החמרה לעלון 20.04.22 - החמרה לעלון 12.12.22 - החמרה לעלון 31.07.24 - החמרה לעלון

לתרופה במאגר משרד הבריאות

ולטסה 8.4 גר'

קישורים נוספים

RxList WebMD Drugs.com